Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BE1116 for VKA Reversal in Japanese Subjects
NCT02281201Phase 3Completed
- Sponsor
- CSL Limited
- Start
- Oct 2014
- Primary completion
- Jan 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of prothrombin complex concentrate in coagulopathy and hemorrhage, sponsored by CSL Limited. Primary endpoint: Percentage of Subjects With a Rapid Reversal of VKA Effect. Started Oct 2014; status: completed.
02
Drugs
prothrombin complex concentrate
03
Conditions
coagulopathyhemorrhage
Beyond the preview
Go deeper on NCT02281201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02281201.